Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma-Reference-Cited by-同舟云学术

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

Published:2012-07-29 Issue:9 Volume:44 Page:1006-1014
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Krauthammer Michael,Kong Yong,Ha Byung Hak,Evans Perry,Bacchiocchi Antonella,McCusker James P,Cheng Elaine,Davis Matthew J,Goh Gerald,Choi Murim,Ariyan Stephan,Narayan Deepak,Dutton-Regester Ken,Capatana Ana,Holman Edna C,Bosenberg Marcus,Sznol Mario,Kluger Harriet M,Brash Douglas E,Stern David F,Materin Miguel A,Lo Roger S,Mane Shrikant,Ma Shuangge,Kidd Kenneth K,Hayward Nicholas K,Lifton Richard P,Schlessinger Joseph,Boggon Titus J,Halaban Ruth

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.2359.pdf

Reference81 articles.

1. Bauer, J. et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res. 24, 345–351 (2011).

2. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).

3. Chapman, P.B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507–2516 (2011).

4. Ribas, A. & Flaherty, K.T. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat. Rev. Clin. Oncol. 8, 426–433 (2011).

5. Jakob, J.A. et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer published online, doi:10.1002/cncr.26724 (16 December 2011).

Cited by 1004 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- (“Triple”) wild type melanomas;European Journal of Cancer;2024-09

2. Heterogeneous pathogenesis of melanoma: BRAF mutations and beyond;Critical Reviews in Oncology/Hematology;2024-09

3. Gender and melanoma subtype‐based prognostic implications of MUC16 and TTN co‐occurrent mutations in melanoma: A retrospective multi‐study analysis;Cancer Medicine;2024-09

4. Tumor-derived RHOA mutants interact with effectors in the GDP-bound state;Nature Communications;2024-08-21

5. Therapeutic advances of targeting receptor tyrosine kinases in cancer;Signal Transduction and Targeted Therapy;2024-08-14